Strata Oncology generates USD 26 million via Series B funding round
Date: 2018-05-27   Author: Dhananjay Punekar  Category: #news

Strata Oncology, a Michigan headquartered precision medicine startup, has reportedly, in its series B round, closed the funding at nearly USD 26 million. If sources are to be believed, Pfizer Venture Investments & Merck Global Health Innovation Fund, LLC led the round of investments. Other investors who were a part of the funding round included Baird Capital, Deerfield Management, Renaissance Venture Capital Fund, and Arboretum Ventures.

For the record, the healthcare startup has raised nearly USD 38 million through an initial round of funding since its launch three years back.

Dan Rhodes, the CEO of Strata, has stated that with major pharma companies such as Merck & Pfizer supporting the company’s investment round, it is quite plausible for the firm to work on the advancement of precision oncology & tumor sequencing projects. He further claimed that the firm will use a part of the proceeds from its fund-raising program to finance its precision oncology network.

A key official of Strata has announced that the investments will also be utilized for developing the firm’s clinical genomic information & software platforms and introducing a study targeted at unravelling the prolonged use of medicines for curing cancer. Sources cite that the precision medicine company is likely to send StrataNGS, a tumor molecular profiling assay, to seek the U.S. FDA’s approval.

As per medical experts, genomic testing is very expensive as clinical trials do not receive extensive healthcare insurance coverage. Strata’s collected funds in this regard, have been projected to help the firm extensively carry out its gene testing activities.

Similar funding round activities are expected to offer the startup opportunities to make use of approved medicines in other types of cancers with a similar genetic make-up.

Analysts are of the view that the investments in the programs run by the startups such as Strata will open up huge growth opportunities for precision medicine market players over the next few years.



About Author


Dhananjay Punekar

Dhananjay Punekar

Dhananjay currently works as a content writer at AlgosOnline. A post graduate in mathematics as well as business administration, he worked as a process executive in Infosys BPO Limited before switching his professional genre. Following his childhood passion, he opted fo...

Read More

More from Dhananjay


Post Recommendents

Walmart and JD.com provide $500m funding to Chinese logistics company
Author: Pankaj Singh

Dada-JD Daojia, a Chinese online grocery delivery service has reportedly raised USD 500 million in a recent funding round led by U.S. retail giant Walmart and Chinese e-commerce company JD.com. Sources inform that the ...


3D Systems & GF Machining team up to develop factory of the future
Author: Saif Ali Bepari

South Carolina based 3D Systems has reportedly announced a partnership with GF Machining Solutions with the aim of redefining how manufacturers think about their manufacturing setup. Sources cite that the new manufactu...


ITV invests USD 1 billion with Hollywood giants to launch NewT
Author: Ojaswita Kutepatil

ITV, a commercial television channel of the United Kingdom has reportedly collaborated with major Hollywood studios including 21st Century Fox, Disney, and others. Two huge Wall Street banks and the billionaire Walton ...